A key goal in influenza research is the design of a universal flu vaccine that affords protection against multiple viral subtypes. Now, two studies report new vaccination strategies that engineer the stem region of haemagglutinin (HA) glycoprotein to elicit antibodies that protect against multiple influenza subtypes in animal models of infection.
http://www.nature.com/nrmicro/journal/vaop/ncurrent/full/nrmicro3553.html
hVIVO is the new name of Retroscreen Virology! (from 15 April 2015). hVIVO is a rapidly growing UK life sciences company pioneering a technology platform which uses human challenge models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled, clinical environment. Our belief is that the best way to understand human disease is by studying it in humans, not laboratory models.
No comments:
Post a Comment